China’s national healthcare regulator recently published new rules that may provide useful guidance for pharmaceutical or medical device companies to enhance compliance controls over sponsorship and donations to healthcare entities, although these companies are not the direct targets of the new regulations.
On 20 October, the National Health and Family Planning Commission (NHFPC) published the Administrative Measures on Accepting Donations for Public Welfare by Healthcare Entities (for Trial Implementation).
The new rules apply to donations between foreign or domestic entities and individuals as donors, and healthcare and family planning entities (healthcare entities) as donees. The donees include healthcare institutions, social public welfare associations, foundations and other charitable social organizations that are supervised by the NHFPC and its local counterparts.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
Business Law Digest is compiled with the assistance of Baker & McKenzie. Readers should not act on this information without seeking professional legal advice. You can contact Baker & McKenzie by e-mailing Danian Zhang (Shanghai) at: danian.zhang@bakermckenzie.com
